Journal of Diabetes & Clinical Practice
Open Access

Apart from diabetes, thyroid dysfunction is the most prevalent endocrine condition during pregnancy. The development of the foetal brain during the embryonic stage depends on thyroid hormones. Preterm birth, hypertension, miscarriage, and low birth weight are just a few of the serious negative outcomes that maternal thyroid dysfunction during pregnancy may have for both the mother and the foetus [1]. With particular reference to existing guidelines on the subject, which we analyse, criticise, and compare against one another, we discuss the impact of thyroid disease on pregnancy in this review as well as the most recent research on how to manage various thyroid conditions during pregnancy and after delivery in order to improve foetal and neonatal outcomes [2]. In order to maintain euthyroidism, overt hypothyroidism and overt hyperthyroidism should be treated adequately during pregnancy. Levothyroxine is frequently used pragmatically to treat subclinical hypothyroidism, albeit there is no conclusive evidence to support this [3]. Whether this has an impact on foetal or maternal outcomes. Treatment for subclinical hyperthyroidism is typically not necessary, although it should be kept in mind that it could indicate a non-thyroidal condition or gestational thyrotoxicosis. Thyroid autoimmune illnesses often get better during pregnancy but frequently get worse or develop after delivery. Thyroid auto-antibodies consequently tend to decline as pregnancy progresses. Instead than using aberrant biochemical data to guide treatment, postpartum thyroiditis should be handled according to the clinical symptoms [4]. The second most prevalent endocrine disorder during pregnancy is thyroid illness, behind diabetes. In iodine-rich populations, the background prevalence of spontaneous hypothyroidism is between and; it affects women more frequently than it does men. About of women experience subclinical hypothyroidism, this is characterised by elevated serum thyroid stimulating hormone levels in the presence of normal thyroid hormone levels [5]. About half the population is affected with sub clinical hyperthyroidism, which is characterised by low serum TSH levels in the absence of hypothalamic and pituitary disease, non-thyroidal illness, or drugs that block TSH release but with normal thyroid hormone levels. The relationship between thyroid disease and pregnancy will be examined in this study, along with the changing body of knowledge regarding how to treat various thyroid problems during pregnancy and after delivery, with a focus on current recommendations in this area. Concerns over the UK's pregnant and child-bearing women's adequate iodine intake have lately been raised. In addition, fresh data from the large longitudinal AVON study in the UK suggests that mild to moderate maternal iodine insufficiency is linked to poorer cognition. Confirming the findings of a smaller Australian investigation. Fish consumption appears to be good for maternal outcomes, such as lowering thyroid autoimmunity in the prenatal and post-partum period and gestational hypertension [6]. This correlation may explain the relationship between increased fish intake in pregnancy and improved cognition in the offspring. Although oily fish's high omega fatty acid content has been given credit for this favourable effect, it's also probable that its high iodine concentration is to blame for its positive effects on thyroid physiology and function. It is still up for debate whether or not pregnant women from areas with a mild to moderate iodine deficiency should take iodine supplements. However, iodine supplementation in expecting mothers from areas with low to moderate iodine levels. Although the evidence for supplements has been positive in a number of research, not all of the investigations utilised rigorous methodologies. These studies have suggested that iodine supplementation has some positive effects on maternal and newborn serum thyroglobulin and thyroid volume in populations with mild-to-moderate iodine deficiency, though data on thyroid function is inconsistent and solid evidence on long-term effects, such as pregnancy outcomes, childhood neurodevelopment, and growth, is lacking. There is some evidence that taking iodine supplements sooner leads to better results. Similarly, no extensive research has looked at how iodine supplementation during nursing affects a child's development. However, an RCT in a hilly region of Morocco with moderate to severe iodine deficiency found that supplementing the mother with one dosage of iodized oil had positive results. On the other hand, it's best to avoid taking iodine supplements in excess. There is evidence that excessive iodine replacement may raise the risk of hypothyroidism, including subclinical hypothyroidism, isolated hypothyroxinaemia, and auto-immune hypothyroidism. Furthermore, because of their fluctuating, and occasionally excessive, iodine concentration, kelp supplements ought to be avoided. The various recommendations appear to agree that daily oral iodine supplementation is necessary throughout pregnancy and breastfeeding. It is crucial to remember that these recommendations were based on urine iodine concentration, which is more effective for assessing the iodine status of populations than for determining the iodine status of specific pregnancies. Even though it can occasionally develop during pregnancy, it is frequently preexistent. The most typical cause is persistent autoimmune thyroiditis. Primary maternal hypothyroidism is characterised by a high TSH level during pregnancy, absent rare exceptions like a pituitary tumour that secretes TSH, thyroid hormone resistance, or a few isolated cases of central hypothyroidism in biologically inactive pregnancies. Even though it can occasionally develop during pregnancy, it is frequently preexistent. The most typical cause is persistent autoimmune thyroiditis. It may also be the outcome of prior radioactive iodine therapy or surgery for thyroid cancer, goitre, or hyperthyroidism. Pregnant women with untreated hypothyroidism have an increased risk of obstetric problems, according to numerous researches. These include placental abruption, anaemia, premature birth, low birth weight, perinatal mortality, pregnancy-induced hypertension, pre-eclampsia and low birth weight. Additionally, cognitive development and IQ quotient have been negatively impacted by hypothyroidism. Thyroid hormone resistance, a few cases of central hypothyroidism with biologically inactive TSH pregnancies, and TSHsecreting pituitary tumours are a few rare exceptions that do not necessarily indicate primary maternal hypothyroidism. Even though it can occasionally develop during pregnancy, it is frequently preexistent. The most typical cause is persistent autoimmune thyroiditis. It may also be the outcome of prior radioactive iodine therapy or surgery for thyroid cancer, goitre, or hyperthyroidism. Pregnant women with untreated hypothyroidism have an increased risk of obstetric problems, according to numerous research. These include placental abruption, anaemia, premature birth, low birth weight, perinatal mortality, pregnancy-induced hypertension, preeclampsia, and postpartum haemorrhage. Additionally, low thyroid hormone levels have been linked to negative impacts on cognitive growth and IQ. Levothyroxine replacement should start as soon as overt hypothyroidism is diagnosed, with the goal of bringing the TSH level into the pregnancy reference range for the particular trimester. Most pregnant women with preexisting hypothyroidism will require levothyroxine dose increases between the first four to eight weeks of pregnancy, and the dose increase often reaches a plateau by week eight. The dose of levothyroxine should be increased as soon as a missed period or positive pregnancy test are confirmed; one way to achieve this is to increase the weekly doses to doses The need for levothyroxine typically peaks in the final weeks of pregnancy before delivery. Gestational diabetes, placental abruption, early pregnancy loss, premature membrane rupturing, and newborn mortality. Prospective investigations in iodine-rich communities have established the possibility of miscarriage, and the possibility of miscarriage seems to be associated with TSH increments that are higher than but outside of the normal range. Some studies have found that the offspring suffer neurodevelopmental problems, but there is conflicting data to support this. In the one interventional research by Lazarus et al., pregnant women were separated into a screening group and a control group; the former had blood samples promptly analysed for thyroid function tests while the latter had their TFTs tested following the end of the pregnancy. When the two groups' children were involved, there was no difference. Similar to this, there was no difference in intelligence quotient measures in the offspring at the ages of three or five years old in a large multicenter double-blind RCT of levothyroxine therapy for subclinical hypothyroidism in pregnancy that has not yet been published. There are few research that look at the effects of subclinical hypothyroidism in young children under the age of three. Based on one study, the ATA suggested that levothyroxine be administered to women with subclinical hypothyroidism who had elevated thyroid peroxidase antibody titres. However, they noted that there was insufficient evidence to support either a recommendation for or against levothyroxine treatment for TPOAb negative women with subclinical hypothyroidism. In fact, the RCT in question by Negro has demonstrated a statistically significant decrease in miscarriages and preterm births. Levothyroxine was started on average at around weeks of gestation, and all miscarriages, with the exception of one, occurred before the weeks, so it is doubtful that the thyroxine therapy played a role in this outcome. The results of this study cannot be readily extended to other populations because it was conducted in Southern Italy, which has an iodine deficiency. Regardless of TPOAb status, the European Thyroid Association and The Endocrine Society suggest levothyroxine replacement in all women with subclinical hypothyroidism because they believe the benefits of treatment outweigh any potential risks. Indeed, the majority opinion among endocrinologists has been to administer levothyroxine to all such women in order to bring their TSH levels within the appropriate range for each trimester. A recent big, population-based prospective Dutch study, nevertheless TFTs should be carried out on a frequent basis for both overt and subclinical hypothyroidism, especially during the first half of pregnancy and if a treatment adjustment is made. In moms with well-controlled hypothyroidism, extra foetal observation is typically not necessary. Levothyroxine dose reduction to pre-pregnancy levels is customarily done right away after childbirth, while some writers argue that this should really happen two weeks after delivery and be followed by more TFTs. Some writers characterise maternal isolated hypothyroxinaemia as TSH levels within the reference range and fT4 levels below it, while other authors define it as a normal TSH with fT4 values in the lowest or even 10th percentile.

1. Ain KB, Mori Y, Refetoff S (1987) Reduced clearance rate of thyroxine-binding globulin (TGB) with increased sialylation: A mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 65: 689-702.

Indexed at, Crossref, Google Scholar

2. Caldwell K L, Pan Y, Mortensen M E , Makhmudov A , Merrill L et al.(2013) Iodine status in pregnant women in the National Children’s Study and in U.S. women (15–44 years), National Health and Nutrition Examination Survey 2005–2010. Thyroid 23:927-937.

Indexed at, Crossref, Google Scholar

3. Lazarus JH , Ammari F, Oretti R, Parkes A B, Richards C J et al.(1997)  Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract 47: 305-308.

Indexed at, Crossref, Google Scholar

4. Cleary Goldman J, Malone F D, Lambert Messerlian G (2008) maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol 112: 85-92.

Indexed at, Crossref, Google Scholar

5. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C (2007) the beneficial effect of L thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 92: 1715-1723.

Indexed at, Crossref, Google Scholar

6. Labadzhyan A, Brent G A, Hershman J M , Leung A M , Kersten I et al. (2014) Thyrotoxicosis of pregnancy. J Clin Transl Endocrinol 1: 140-144.

Indexed at, Crossref, Google Scholar